FDA PreCheck Pilot Opens a New Lane for Domestic Facility Development

FDA's PreCheck Pilot Program repositions regulatory engagement from a post-construction checkpoint to an active input in facility development, a shift that plant heads and QA directors planning new U.S. sites cannot afford to overlook. By accepting applications from February 1, 2026, the agency is signaling that GMP compliance strategy and facility design should be converging far earlier in the project lifecycle than current industry practice typically demands. For manufacturers already modelling timelines to first commercial batch, the program introduces a variable that could materially compress or extend those projections depending on how quickly teams move to engage.

The FDA PreCheck Pilot Program will select an initial cohort of new pharmaceutical manufacturing facilities and begin conducting PreCheck activities in 2026. Selection criteria are explicitly tied to national priorities: the types of pharmaceutical products to be manufactured, the phase of facility development at time of application, the timeline to producing pharmaceutical products for the U.S. market, and innovation in facility development. The agency has not yet published a fixed cohort size or a ranked weighting of those criteria, with additional details scheduled for release on the application website on February 1, 2026. Regulatory affairs leads should treat that date as a hard planning milestone, not a passive information release.

The program's design reflects direct industry input. FDA incorporated stakeholder feedback gathered during the September 30, 2025 public meeting titled "Onshoring Manufacturing of Drugs and Biological Products" and through public comments submitted via the Federal Register. Overall sentiment from industry was positive, with a consistent request for early engagement during facility development phases rather than engagement timed to a specific product application. The resulting program structure, which decouples facility assessments from product application submissions, directly addresses that request and aligns with the continuous improvement principles embedded in ICH Q10 pharmaceutical quality systems.

For QA and regulatory affairs functions, the practical implication is a need to reassess how facility qualification documentation, process validation planning, and inspection readiness programs are sequenced. Facilities selected for the pilot will undergo FDA PreCheck activities ahead of any product-specific submission, meaning that the agency's assessors will be evaluating site readiness, quality systems architecture, and GMP infrastructure against a forward-looking standard rather than a retrospective one. Teams accustomed to structuring 21 CFR Part 211 compliance packages around a defined product dossier will need to develop facility-level narratives that stand independently of product data.

FDA stated that the PreCheck Program will create a more predictable regulatory pathway, accelerate domestic pharmaceutical manufacturing, and protect patient safety. The broader supply chain context is significant: the program is one component of a sustained federal effort to reduce dependence on foreign manufacturing sources and increase the resilience of the U.S. pharmaceutical supply. Manufacturers evaluating site selection decisions, capital allocation, or partnership structures for new U.S. capacity should factor PreCheck eligibility into those assessments now, ahead of the February 1 application opening.